Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Blisters

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    48 result(s) found for: Blisters. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2005-000897-38 Sponsor Protocol Number: DAM/001/05 Start Date*: 2005-05-18
    Sponsor Name:FARMACEUTICI DAMOR
    Full Title: Open-label, controlled, randomised, multicentre, parallel group clinical trial of efficacy and tolerability of Fitostimoline soaked gauzes, Fitostimoline cream and Citrizan gel in the topical...
    Medical condition: Topical treatment of second-degree superficial cutaneous burns
    Disease: Version SOC Term Classification Code Term Level
    6.1 10006802 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-004304-12 Sponsor Protocol Number: 2260/2006 Start Date*: 2007-09-25
    Sponsor Name:AZIENDA OSPEDALIERA PISANA
    Full Title: Pilot study, randomised, open-label, monocentre, case vs control study to assess the effect of topically and parenterally Heparin administration treatment in superficial and deep second grade bu...
    Medical condition: Superficial and deep second degree burns.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006802 Burns second degree LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-006658-24 Sponsor Protocol Number: 8024 Start Date*: 2009-03-05
    Sponsor Name:University of Nottingham
    Full Title: A randomised controlled trial to compare the safety and effectiveness of doxycycline (200 mg/day) with prednisolone (0.5 mg/kg/day) for initial treatment of bullous pemphigoid
    Medical condition: BP is a serious condition with a significant associated morbidity and mortality rate. Widespread tense and haemorrhagic blisters, skin erosions and severe itching cause patients a great deal of dis...
    Disease: Version SOC Term Classification Code Term Level
    14.0 10040785 - Skin and subcutaneous tissue disorders 10006568 Bullous pemphigoid NOS LLT
    14.0 10040785 - Skin and subcutaneous tissue disorders 10006567 Bullous pemphigoid LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-002870-27 Sponsor Protocol Number: ASCAB Start Date*: 2018-12-11
    Sponsor Name:Dept. of Plastic Surgery and Burns Treatment, Copenhagen University Hospital Rigshospitalet
    Full Title: Adipose-derived Stem Cells in the treatment of Acute Burns (ASCAB)
    Medical condition: Skin burns.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004863 10039798 Second degree burns LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-004316-31 Sponsor Protocol Number: FPP4-DE-401 Start Date*: 2009-02-23
    Sponsor Name:Novartis Consumer Health S.A.
    Full Title: A randomised, double-blind, vehicle controlled, single centre, parallel group, comparative study of the efficacy of penciclovir 10 mg/g (1%) cream in preventing the appearance of classical lesions ...
    Medical condition: Cold Sores caused by the herpes simplex virus (HSV) type 1.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10049352 Cold sores lip LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-004557-15 Sponsor Protocol Number: 08.0278-38 Start Date*: 2008-11-25
    Sponsor Name:Merckle Recordati GmbH
    Full Title: 10 days clinical pilot study to investigate the wound healing efficacy of Mirfulan® ointment (containing zinc oxide and cod liver) in an intra-individual comparison with a placebo, zinc oxide and c...
    Medical condition: healthy volunteers Mirfulan® ointment is a topical formulation for the treatment of wounds. Indications for the application of Mirfulan® are treatment of non-infectious acute and subacute skin dam...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-000756-42 Sponsor Protocol Number: MEX0111 Start Date*: Information not available in EudraCT
    Sponsor Name:Dompé s.p.a.
    Full Title: A phase 2, multicentre, single arm, pilot study to assess the efficacy and the safety of 150 mg twice a day oral DF2156A in patients with active bullous pemphigoid.
    Medical condition: active bullous pemphigoid
    Disease: Version SOC Term Classification Code Term Level
    14.0 10040785 - Skin and subcutaneous tissue disorders 10006567 Bullous pemphigoid LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-001059-37 Sponsor Protocol Number: AKST4290-221 Start Date*: 2019-06-21
    Sponsor Name:Alkahest, Inc.
    Full Title: Double-Blind, Randomized, Placebo-Controlled Trial of AKST4290 for Adjunctive Treatment of Mild to Moderate Bullous Pemphigoid
    Medical condition: Mild to Moderate Bullous Pemphigoid
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10006567 Bullous pemphigoid LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2008-005115-17 Sponsor Protocol Number: CS I-020502/02 Start Date*: 2009-09-23
    Sponsor Name:Kuros Biosurgery AG
    Full Title: A phase 2b, multi-centre, randomized, intra-patient-controlled dose-finding study of I-020502 in patients undergoing autologous meshed skin grafting.
    Medical condition: acute wounds / deep partial and full thickness burns
    Disease: Version SOC Term Classification Code Term Level
    9.1 10043418 Thermal burns HLT
    9.1 10006802 Burns second degree LLT
    9.1 10006803 Burns third degree LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-000261-36 Sponsor Protocol Number: 1.0 Start Date*: 2021-01-27
    Sponsor Name:Holostem Terapie Avanzate s.r.l.
    Full Title: MULTICENTRE, OPEN-LABEL, UNCONTROLLED, PIVOTAL CLINICAL TRIAL TO CONFIRM THE EFFICACY AND SAFETY OF AUTOLOGOUS FIBRINCULTURED EPIDERMAL GRAFTS CONTAINING EPIDERMAL STEM CELLS GENETICALLY MODIFIED F...
    Medical condition: Inherited Epidermolysis Bullosa (EB) is a group of rare, devastating genetic disorders characterized by structural and mechanical fragility of skin and mucosal membranes, impairing the patient's qu...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10014989 Epidermolysis bullosa PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Ongoing) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-002135-26 Sponsor Protocol Number: 4PH/2011/002 Start Date*: 2012-02-16
    Sponsor Name:AESCULAPIUS FARMACEUTICI S.R.L.
    Full Title: Efficacy and Safety of Acyclovir 5 Lipstick (Contra) in Treatment of Skin Infections Provoked by Herpes Simplex. A Randomised, Double-blind, Placebo Controlled, Parallel Group Study.
    Medical condition: History of recurrent herpes labialis with at least 3 recurrences during the past 12 months and typically (>50% of episodes) associated with prodromal symptoms
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10019942 Herpes labialis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-004015-21 Sponsor Protocol Number: CA-P-3978-01 Start Date*: 2006-08-31
    Sponsor Name:Johnson & Johnson Consumer and Personal Products Worldwide
    Full Title: Randomized Clinical Study Comparing Compeed Cold Sore Patch to Zovirax Cream 5% in the Treatment of Herpes Labialis
    Medical condition: Herpes Labialis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10019942 Herpes labialis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2007-002060-10 Sponsor Protocol Number: NN-PEN-003 Start Date*: 2007-06-29
    Sponsor Name:ikfe GmbH
    Full Title: Pharmacokinetics and Pharmacodynamics of subcutaneous applied insulin aspart administered with the FlexPen® insulin pen compared to inhaled insulin administered with the Exubera® device
    Medical condition: Type 1 and Type 2 Diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012614 Diabetes mellitus NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-005987-67 Sponsor Protocol Number: AK802 Start Date*: 2021-12-22
    Sponsor Name:Akari Therapeutics Plc
    Full Title: A randomized, part A partial blinded and part B double blinded, placebo-controlled 24-week clinical study to evaluate the efficacy and safety of nomacopan therapy in adult patients with bullous pem...
    Medical condition: moderate to severe bullous pemphigoid
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10006567 Bullous pemphigoid LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) NL (Ongoing)
    Trial results: View results
    EudraCT Number: 2008-004695-49 Sponsor Protocol Number: 08-01 / Ter-C Start Date*: 2009-01-13
    Sponsor Name:Dermapharm AG
    Full Title: Doppelblinde, randomisierte klinische Studie zum Vergleich der Wirksamkeit und Verträglichkeit von Terbinafin Creme 1% vs. Lamisil® Creme vs. Grundlage bei Patienten mit Tinea pedis
    Medical condition: Tinea pedis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10043873 Tinea pedis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-000362-38 Sponsor Protocol Number: BBW-11 Start Date*: 2012-06-18
    Sponsor Name:Birken AG
    Full Title: Open, Blindly Evaluated, Prospective, Controlled, Randomized, Multicenter Phase III Clinical Trial to Compare Intra-individually the Efficacy and Tolerance of Oleogel-S10 versus Standard of Care in...
    Medical condition: Superficial partial-thickness (grade 2a) burn wounds
    Disease: Version SOC Term Classification Code Term Level
    14.1 10022117 - Injury, poisoning and procedural complications 10006802 Burns second degree PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-001097-27 Sponsor Protocol Number: MONO-01 Start Date*: 2005-09-29
    Sponsor Name:Bio-Gels Pharmaceuticals
    Full Title: A Study of the Clinical Activity of Monocaprin/Doxycycline Gel on Cold Sores
    Medical condition: Herpes simplex virus (HSV) has plagued mankind worldwide for thousands of years. Once HSV enters the body, it penetrates vulnerable cells in the lower layers of human skin tissue and replicates its...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: IS (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-000901-21 Sponsor Protocol Number: 2013.03 Start Date*: 2013-10-24
    Sponsor Name:Rode Kruis Ziekenhuis
    Full Title: A randomized clinical trial on the effectiveness, cost-effectiveness and quality of life of Flaminal® versus Flammazine® in the treatment of superficial and deep partial thickness burns
    Medical condition: Patients with partial thickness burns and/ or mixed depth of partial and full thickness burns
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004863 10015723 Extensive burns LLT
    14.1 100000004863 10006796 Burns eyes LLT
    14.1 100000004863 10006795 Burns extensive LLT
    16.0 100000004863 10006794 Burns classified according to extent of body surface involved LLT
    14.1 100000004863 10043441 Third degree burns LLT
    14.1 100000004863 10006801 Burns of multiple specified sites, unspecified degree LLT
    16.0 100000004863 10012087 Deep necrosis of underlying tissues due to burns (dtd) of multiple specified sites w/o mention lobp LLT
    14.1 100000004863 10028175 Multiple burns LLT
    14.1 100000004863 10039798 Second degree burns LLT
    16.0 100000004863 10031700 Other burns of eyelids and periocular area LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-002836-18 Sponsor Protocol Number: AK801 Start Date*: 2018-05-07
    Sponsor Name:Akari Therapeutics Plc.
    Full Title: A Phase IIa open label single arm study of safety and efficacy of rVA576 in adult mild to moderate Bullous Pemphigoid subjects
    Medical condition: Mild to Moderate Bullous Pemphigoid
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10006567 Bullous pemphigoid LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-021144-17 Sponsor Protocol Number: EA10-01-998 Start Date*: 2011-01-12
    Sponsor Name:Engelhard Arzneimittel GmbH & Co. KG
    Full Title: A phase III, multi-center, double-blind, randomized, vehicle controlled trial in a parallel-group design to evaluate the efficacy and safety of two formulations of Muxan containing 0.5 % or 1 % chl...
    Medical condition: Male or female patients, aged 12 years or older (first part of the trial: only patients aged 18 years or older), with an adequate history of recurrent herpes labialis and an acute episode of herpes...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10019942 Herpes labialis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 19:48:12 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA